Currently, the non-specific platinum-based chemotherapy with or without immunotherapy remains a standard first-line treatment for advanced HER2-altered non-small cell lung cancer (NSCLC), based on studies in general patient populations without sensitizing molecular alterations.14 The gene discussed is ERBB2; the disease is non-small cell lung carcinoma.